Maximize Your Chances Of Successful Outcomes

RGCC CAMBISeq is a comprehensive test which offers next-generation analysis on both DNA and RNA. By analyzing over 523 genes, this test predicts how your body will respond to immunotherapy, ensuring that your treatment is precisely tailored to your unique genetic makeup. The test result is personalized and targeted care that maximizes your chances of successful treatment outcomes.

Sample Type
Blood, Tissue, FFPE tissue
Sample Size
10-15ml blood, minimum 400mg tissue, minimum 100mg FFPE tissue
All Types
Turnaround Time
30 days

How it works?

RGCC CAMBISeq transforms your cancer treatment journey using your genetic blueprint.

Next-generation sequencing (NGS) is a powerful technology used in molecular biology to sequence DNA and RNA much more quickly and at a lower cost compared to traditional sequencing methods.

Specializing in identifying variants in over 523 genes, this test provides detailed genetic insights crucial for personalized cancer treatment.

The test results offer insights into the DNA makeup of a tumor which decides how a patient will respond to various forms of immunotherapy and cancer treatments.

How it is done?

RGCC CAMBISeq is a cutting-edge genetic analysis test that examines 523 cancer-relevant genes from both DNA and RNA.
The test calculates essential indicators such as tumor mutational burden (TMB) and microsatellite instability (MSI), providing a comprehensive view of the genetic landscape.
The test uses both DNA and RNA panels, the TruSight Oncology 500 DNA panel and TruSight Tumor 170 RNA panel to test for variants.
The incorporation of unique molecular identifiers (UMIs) during DNA library preparation enhances specificity and minimizes errors, enabling the detection of variants at low variant allele frequencies (VAF).

Why choose RGCC CAMBISeq®?

RGCC CAMBISeq empowers scientists and clinicians to decode crucial genetic information and calculate the TMB score accurately. By minimizing errors using UMIs, RGCC CAMBISeq ensures high specificity in its results.

RGCC CAMBISeq can detect genetic alterations present in cancer cells at very low frequencies with coverage up to 1000 to 2500 X as required, including rare mutations or variants that may be missed by other diagnostic methods.

With the invaluable genetic insights provided by RGCC CAMBISeq, clinicians can tailor therapies precisely, offering the most effective and personalized care for individuals facing a cancer diagnosis.

Which cancers are tested?

RGCC CAMBISeq which helps to determine if a patient may respond well to immunotherapy or targeted therapy covers different types of cancers like lung, breast, colon, myeloid, sarcoma etc.,

The test applies to all types of cancer and is not just limited to the following.

Head & Neck Cancer
Liver Cancer
Kidney Cancer
Prostate Cancer
Pancreatic Cancer
Colon Cancer
Lung Cancer
Gastric Cancer
Colorectal Cancer
Bladder Cancer
Breast Cancer


Book an appointment

The first step towards personalized cancer care is scheduling an appointment with us.


30 minutes value packed consultation

Upon booking the appointment, you get a consultation with our RGCC experts to assess your cancer status.


Finding the right tests

We guide you through the process of selecting the most effective tests for your specific cancer.


Personalized results

We deliver precise results that guide treatment decisions and enhance outcomes.

Why clinicians prefer RGCC CAMBISeq® than other similar tests?

Dr. Mohan Vamsy

“With tests like CAMBISeq, which identifies more than 500 oncogenes and helps determine that any changes in these oncogenes could lead to cancer. Now with these advanced tools like Next Generation Sequencing, we can pinpoint the exact gene and its mutation that is responsible for causing cancer. “

Request a Second Opinion

Our RGCC accredited experts are here to help you with their expertise and guide you in your fight against cancer.

Start your personalized cancer journey with us!

Our cutting edge diagnostics and personalised tests makes a meaningful difference in the fight against cancer.

    Frequently Asked Questions

    • Can tests be conducted during ongoing treatment?

      Absolutely, tests can be performed while undergoing treatment to assess the effectiveness of the treatment against cancer.

    • What happens to my blood sample post-testing?

      Your blood sample undergoes processing in cutting-edge laboratories by scientists and technicians to deliver insights into your cancer cells.

    • Is a blood sample sufficient?

      Yes, all RGCC tests utilize blood samples. However, certain cancers, like glioblastoma and brain tumors, may require additional samples such as CSF or tissue. Otherwise, a peripheral blood sample alone is enough.

    • Can the origin of a tumor be determined by the tests?

      Yes, tests like aCGH can pinpoint the origin of an unknown primary tumor by analyzing genetic abnormalities present in tumor cells.

    • What tests are effective in identifying the emergence of secondary tumors?

      RGCC Metastat is an effective test for identifying secondary tumors development and its potential location. It helps detect secondary tumors through analyzing Circulating Tumor Cells (CTCs) in the bloodstream. The test provides valuable insights into disease progression and metastasis.

    • How do tests personalize cancer treatment?

      Tests personalize treatment regimens by providing crucial information on drugs and therapies tailored to effectively target cancer cells.

    • What are CTCs and CSCs?

      Circulating Tumor Cells (CTCs) are cancer cells that have detached from the primary tumor and circulate in the bloodstream. Cancer Stem Cells (CSCs) are a subpopulation of CTCs and both serve as biomarkers for cancer.

    • Do tests reveal drug response and sensitivity to immunotherapy?

      Tests like ChemoSNiP and CAMBISeq provide information on the body’s response to the drugs and sensitivity to immunotherapy.

    RGCC CAMBISeq is your ally in the fight against cancer

    Decoding your genetic information, this test identifies the treatment option that aligns best with your unique needs. With insights from this test, clinicians can craft personalized therapies tailored to effectively target cancer, ultimately enhancing patient outcomes and quality of life.